ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Lotus Pharmaceuticals Inc (PK)

Lotus Pharmaceuticals Inc (PK) (LTUS)

0.0053
0.002
(60.61%)
Cerrado 27 Enero 3:00PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
0.0053
Postura de Compra
0.0016
Postura de Venta
0.0053
Volume Operado de la Acción
102,500
0.0053 Rango del Día 0.0053
0.0006 Rango de 52 semanas 0.0075
Precio Anterior
0.0033
Precio de Apertura
0.0053
Última hora de negociación
Volumen promedio (3 m)
71,965
Volumen financiero
US$ 543
Precio Promedio Ponderado
0.0053

LTUS Últimas noticias

Public Announcement From Lotus Pharmaceuticals, Inc.

Public Announcement From Lotus Pharmaceuticals, Inc. PR Newswire BEIJING, April 10, 2012 BEIJING, April 10, 2012 /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" or the...

Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building

Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building PR Newswire BEIJING, Jan. 4, 2012 BEIJING, Jan. 4, 2012...

Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results

Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results PR Newswire BEIJING, Nov. 11, 2011 BEIJING, Nov. 11, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB:...

Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results

Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results PR Newswire BEIJING, Aug. 15, 2011 BEIJING, Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc...

Lotus Pharmaceuticals Announces First Quarter Fiscal 2011 Financial Results

Lotus Pharmaceuticals Announces First Quarter Fiscal 2011 Financial Results PR Newswire BEIJING, May 16, 2011 BEIJING, May 16, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc...

/C O R R E C T I O N -- Lotus Pharmaceuticals, Inc./

/C O R R E C T I O N -- Lotus Pharmaceuticals, Inc./ PR Newswire BEIJING, April 25, 2011 In the news release, Lotus Pharmaceuticals Responds to Investor Concerns in Exclusive Interview, issued...

Lotus Pharmaceuticals Responds to Investor Concerns in Exclusive Interview

Lotus Pharmaceuticals Responds to Investor Concerns in Exclusive Interview PR Newswire BEIJING, April 25, 2011 BEIJING, April 25, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc...

RedChip Virtual Equities Conference Starts Today

ORLANDO, Fla., April 19, 2011 (GLOBE NEWSWIRE) -- RedChip Companies, Inc., an international, small-cap research and financial public relations firm, today announced the start of its Small-Cap...

Stephen Moore and David Morgan to Keynote RedChip's Virtual Equities Conference

ORLANDO, Fla., April 15, 2011 (GLOBE NEWSWIRE) -- RedChip Companies, Inc., an international, small-cap research and financial public relations firm, today announced that Stephen Moore and David...

Fourteen Emerging Growth Companies to Present at RedChip's Virtual Equities Conference

ORLANDO, Fla., April 12, 2011 (GLOBE NEWSWIRE) -- RedChip Companies, Inc., an international, small-cap research and financial public relations firm, today announced the presenter list for its...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.00260.60606060610.00330.00530.00163697500.0033CS
40.00132533.33333333330.0039750.00620.0016722960.00363452CS
120.0015541.33333333330.003750.0070.0006719650.00307529CS
260.002482.75862068970.00290.0070.0006706540.00311742CS
520.001851.42857142860.00350.00750.0006500010.00328413CS
156-0.01285-70.79889807160.018150.021850.0006298560.00610012CS
260-0.009-62.93706293710.01430.220.0006503490.05056142CS

LTUS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Lotus Pharmaceuticals (PK)?
El precio actual de las acciones de Lotus Pharmaceuticals (PK) es US$ 0.0053
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Lotus Pharmaceuticals (PK)?
Lotus Pharmaceuticals (PK) ha negociado en un rango de US$ 0.0006 a US$ 0.0075 durante el último año

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TGICTriad Guaranty Inc (CE)
US$ 0.05
(49,900.00%)
1.4k
NOUVNouveau Life Pharmaceuticals Inc (PK)
US$ 0.0002
(19,900.00%)
4.31M
ATYGAtlas Technology Group Inc (PK)
US$ 0.0002
(19,900.00%)
9k
JFTHJapan Food Tech Holdings Inc (CE)
US$ 0.0002
(19,900.00%)
255
ONCIOn4 Communications Inc (PK)
US$ 0.0001
(9,900.00%)
16.82M
SPECSpectaire Holdings Inc (CE)
US$ 0.000001
(-99.95%)
1.99k
TMPOQTempo Automation Holdings Inc (CE)
US$ 0.000001
(-99.89%)
452
FUVVArcimoto Inc (CE)
US$ 0.000001
(-99.50%)
336
SAFSSafer Shot Inc (CE)
US$ 0.000001
(-99.00%)
2M
JAMNJammin Java Corp (PK)
US$ 0.000001
(-99.00%)
39k
TKMOTekumo Inc (PK)
US$ 0.0004
(0.00%)
244.5M
HMBLHUMBL Inc (PK)
US$ 0.00075
(-6.25%)
219.57M
PDGOParadigm Oil and Gas Inc (PK)
US$ 0.0002
(33.33%)
215.18M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.000001
(-99.00%)
195.11M
DPLSDarkPulse Inc (PK)
US$ 0.0006
(-14.29%)
182.43M

LTUS Discussion

Ver más
wooqa wooqa 6 meses hace
LTUS .0038
👍️0
wooqa wooqa 6 meses hace
LTUS .003
👍️0
wooqa wooqa 7 meses hace
LTUS .0006
👍️0
threewheeler threewheeler 2 años hace
LTUS SECURITY DETAILS fantastic float now
Share Structure
Market Cap Market Cap
24,250,640
08/03/2022
Authorized Shares
3,000,000,000
08/03/2022
Outstanding Shares
2,694,515,543 250m gone
08/03/2022
Restricted
2,681,123,970
08/03/2022
Unrestricted
13,391,573 250m gone from float as well
08/03/2022
Held at DTC
12,913,385
08/03/2022 Authorized Shares
3,000,000,000
11/28/2021
Outstanding Shares
2,944,515,543
11/28/2021
Restricted
2,681,123,970
11/28/2021
Unrestricted
263,391,573
11/28/2021
👍️0
threewheeler threewheeler 3 años hace
BUSINESS DESCRIPTION
Lotus Pharmaceuticals, Inc. is a development stage company actively seeking an acquisition partner in a 21st century emerging growth industry company.
👍️0
threewheeler threewheeler 3 años hace
LTUS SECURITY DETAILS
Share Structure
Market Cap Market Cap
68,459,986
11/26/2021
Authorized Shares
3,000,000,000
11/28/2021
Outstanding Shares
2,944,515,543
11/28/2021
Restricted
2,681,123,970
11/28/2021
Unrestricted
263,391,573
11/28/2021
Held at DTC
12,903,385
11/28/2021
👍️0
teampenny teampenny 3 años hace
no clue. I am seeing $10-20k bids last week or so. 13M held at DTC, Pink Current. https://www.otcmarkets.com/stock/LTUS/security
👍️0
michaelstl michaelstl 3 años hace
Here we go again. Anyone know what's going on?
👍️0
Golden Cross Golden Cross 4 años hace
LTUS Pink Current Today
https://www.otcmarkets.com/stock/LTUS/disclosure



👍️0
michaelstl michaelstl 4 años hace
They state in the quarterly report that this is the first time since 2014 that they are able to pay a dividend? I hope this is true!

https://www.lotuspharm.com/
Look at news and the quarterly report released today.
👍️0
michaelstl michaelstl 4 años hace
Earnings Released today

https://www.lotuspharm.com/Media/lotus-q121-earningsen-callsent.pdf
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Great update today!!! Looking forward to news $LTUS https://www.otcmarkets.com/stock/LTUS/news/Lotus-Looking-at-Land-Development?id=301689
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Very nice news didn’t see this until now $LTUS
👍️0
michaelstl michaelstl 4 años hace
Very Big News!!

https://finance.yahoo.com/news/lotus-pharmaceuticals-inc-current-otc-121200677.html
👍️0
michaelstl michaelstl 4 años hace
NEWSROOM
MONTHLY SALES REPORT FOR FEB 2021
POSTED ON 10.3.2021
Lotus today announced that its consolidated sales for February 2021 was NT$1,015,941 thousand, delivering a 95.4% growth over the same period last year. Its consolidated sales YTD’21 has increased by 75.8% YoY and reached NT$2.2 billion.
👍️0
michaelstl michaelstl 4 años hace
Up 125% in two days. Closed on the High!
👍️0
michaelstl michaelstl 4 años hace
Lotus Pharmaceutical filing Nashville TN USA office

https://marketexclusive.com/lotus-pharmaceuticals-inc-otcmktsltus-files-an-8-k-other-events/2020/02/
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Very nice close today!!! What a move!!! $LTUS
👍️0
The Night Stalker The Night Stalker 4 años hace
https://www.stockscores.com/chart.asp?TickerSymbol=ltus&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 4 años hace
wow
👍️0
michaelstl michaelstl 4 años hace
Selling at 1.45X Earnings?


Is it true that this is selling for this very very low PE?
👍️0
michaelstl michaelstl 4 años hace
Up 85%?

I have had this stock for years!!! It was up as much as 85% today?
Does anybody know what is going on?
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Good close today $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Nice Green Day so far!!! $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Was a great day up until somebody dumped those 10K shares at the bid $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Looking good today good morning everyone $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Bought more $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Somebody is loading this one big time here. $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
Thank you yes DM me $LTUS
👍️0
makinezmoney makinezmoney 4 años hace
$LTUS : Got another banger for you..............


If you're interested in it.


I can tell you later.


But make sure you confirm you get before you alert the masses.



Will only send in PM but I've been on it.



GO $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
It’s definitely an undiscovered gem one of the most beautiful $LTUS
👍️0
makinezmoney makinezmoney 4 años hace
$LTUS: It is .............


Almost as beautiful as $NATUF



But thats just me.......... people see ROUGH......... I only see Diamonds.



One by one they unearth themselves and then people follow afterwards



GO $LTUS
👍️0
TradeSmart.ai TradeSmart.ai 4 años hace
What a beauty this one, added $LTUS
👍️0
cyanus cyanus 4 años hace
Highest volume since 4/10/2012
Today volume 1,138,000 so far, had touched 2,000,000 shares back then at $0.179 price.
Hmmm :)
👍️0
makinezmoney makinezmoney 4 años hace
$LTUS: Huge volume going here.......... lets go


Gonna run to $1



GO $LTUS
👍️0
TB87 TB87 4 años hace
very high potential with an addition of a few backers
👍️0
ANTI-BAGHOLDER ANTI-BAGHOLDER 4 años hace
LTUS with a verified profile on OTC markets. Looks like updates are on the way.
👍️0
Sobek Sobek 5 años hace
Anyone figure out who the new CEO is? All I come up with is a guy out of Nashville who is building up a rehab and just raised over a hundred grand this week in a charity concert. I reached out but no response yet.
👍️0
willlbone willlbone 5 años hace
LaPus Pharma just popped like a zit.
👍️0
HDOGTX HDOGTX 5 años hace
LTUS New officers posted on NEV SOS

https://esos.nv.gov/EntitySearch/BusinessFilingHistroy?businessid=505279

https://www.otcmarkets.com/stock/LTUS/profile
👍️0
swampboots swampboots 6 años hace
LTUS would have to have the only drug which cures cancer for me to get my money to even.
👍️0
Steppenwolf$$$ Steppenwolf$$$ 6 años hace
WILL MAKE LTUS MILLIONS YEARLY
👍️0
Steppenwolf$$$ Steppenwolf$$$ 6 años hace
Hacho Hathcikian, Executive Vice President at Alvogen in the CEE regions, said: “The Lenalidomide launch is a major landmark for Alvogen in the CEE region as we are the first generic pharmaceutical company to launch the generic of Revlimid™ in our major markets. Patients now finally have access to an affordable and high-quality generic alternative of this leading oncology drug. Adding Lenalidomide to our portfolio also enhances our commitment to be one of the key oncology players in the CEE region.”

Revlimid™ is indicated for several hematological malignancies including multiple myeloma and is the biggest-selling oncology drug with approximately $9.8 billion sales globally.

Revlimid™ is a trademark of Celgene Corporation
👍️0
Steppenwolf$$$ Steppenwolf$$$ 6 años hace
FEBRUARY 12, 2019
Alvogen
launches
the
first
generic
equivalent
to
Revlimid™
in
Europe
Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.

Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline
👍️0
Steppenwolf$$$ Steppenwolf$$$ 6 años hace
https://alvogen.com/newsroom/alvogen-and-lotus-launch-the-first-generic-equivalent-to-revlimid
👍️0
Steppenwolf$$$ Steppenwolf$$$ 6 años hace
$LTUS Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, $5B COMPANY https://alvogen.com/newsroom
👍️0
Moving On Moving On 6 años hace
I have been sitting on shares for a year or so and noticed some movement. What do you think this means.
👍️0
Steppenwolf$$$ Steppenwolf$$$ 6 años hace
LTUS Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, $5B COMPANY FEBRUARY 12, 2019
Alvogen
launches
the
first
generic
equivalent
to
Revlimid™
in
Europe
Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.

Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline.
👍️0
danjay50 danjay50 7 años hace
It's OK. The BEST is yet to come
👍️0
gumzsa gumzsa 7 años hace
.0165
👍️0

Su Consulta Reciente

Delayed Upgrade Clock